Glenmark Pharmaceuticals Ltd.
₹1,866.10
Last updated: 21 Nov, 2025, 02:09 PM
ShareGLENMARK Income statement
All values in ₹ Cr.
| FY 25 | FY 24 | FY 23 | FY 22 | FY 21 | FY 20 | FY 19 | |
|---|---|---|---|---|---|---|---|
| Sales | 9,226 | 7,891 | 8,221 | 8,142 | 7,568 |  | |
| Expenses | 6,982 | 6,649 | 6,748 | 6,453 | 5,678 | | |
| Operating Profit | 2,244 | 1,242 | 1,473 | 1,688 | 1,890 | | |
| OPM % | 23.42 | 13.71 | 16 | 19.28 | 23.74 | | |
| Other Income | 177.20 | 6,238 | 490.07 | 1,045 | 470.13 | | |
| EBITDA | 2,601 | 2,410 | 2,459 | 2,303 | 2,287 | | |
| Interest | 48.73 | 277.11 | 206.82 | 236.04 | 265.90 | | |
| Depreciation | 218.63 | 202.16 | 184.15 | 159.70 | 150.82 | | |
| Profit Before Tax | 2,154 | 7,001 | 1,572 | 2,337 | 1,944 | | |
| Tax % | 25.24 | 26.19 | 23.10 | 14.53 | 15.14 | | |
| Net Profit | 1,610 | 5,167 | 1,209 | 1,998 | 1,649 | | |
| EPS | 57.07 | 183.13 | 42.84 | 70.80 | 58.46 | | |
| Dividend Payout % | 4.38 | 1.37 | 5.84 | 3.53 | 4.28 | | |
GLENMARK Balance sheet
All values in ₹ Cr.
| FY 25 | FY 24 | FY 23 | FY 22 | FY 21 | FY 20 | FY 19 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | | |
| Reserves | 24,476 | 22,940 | 17,849 | 16,710 | 14,781 | | |
| Minority Interest | -- | -- | -- | -- | -- | | |
| Non Current Liabilities | 283.42 | 154.39 | 3,067 | 2,735 | 3,305 | | |
| Current Liabilities | 3,246 | 4,289 | 3,642 | 3,441 | 2,503 | | |
| Total Liabilities | 28,033 | 27,414 | 24,586 | 22,914 | 20,618 | | |
| Non Current Assets | 23,256 | 22,733 | 20,201 | 18,512 | 15,708 | | |
| Current Assets | 4,778 | 4,681 | 4,385 | 4,403 | 4,909 | | |
| Total Assets | 28,033 | 27,414 | 24,586 | 22,914 | 20,618 | | |
| Contingent Liabilities | 4,308 | 2,658 | 3,923 | 3,700 | 4,013 | | |
GLENMARK Cash flow
All values in ₹ Cr.
| FY 25 | FY 24 | FY 23 | FY 22 | FY 21 | FY 20 | FY 19 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 588.80 | -495.45 | 1,474 | 1,216 | 1,243 | | |
| Cash from Investment Activity | -489.52 | 3,197 | -431.47 | -896.92 | -1,235 | | |
| Cash from Financing Activity | -95.41 | -2,666 | -978.50 | -305.12 | -80.79 | | |
| Net Cash Flow | 3.49 | 35.27 | 64.05 | 13.93 | -72.57 | | |
GLENMARK Ratio Analysis
| FY 25 | FY 24 | FY 23 | FY 22 | FY 21 | FY 20 | FY 19 | |
|---|---|---|---|---|---|---|---|
| Basic EPS (₹) | 57.07 | 183.13 | 42.84 | 70.80 | 58.46 | | |
| Diluted EPS (₹) | 57.07 | 183.13 | 42.84 | 70.80 | 58.46 | | |
| Cash EPS (₹) | 64.82 | 190.29 | 49.36 | 76.46 | 63.80 | | |
| Book Value Per Share (₹) | 868.42 | 813.99 | 633.57 | 593.21 | 524.85 | | |
| Dividend Per Share | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 | | |
| Cash Flow Per Share | 20.87 | -17.56 | 52.24 | 43.10 | 44.07 | | |
| Current Ratio | 1.47 | 1.09 | 1.20 | 1.28 | 1.96 | | |
